Overview

Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer

Status:
RECRUITING
Trial end date:
2026-06-15
Target enrollment:
Participant gender:
Summary
The PEARL Pilot is a phase II open-label trial. Participants will receive a single high-dose (25 mg) of psilocybin in the context of Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy.
Phase:
PHASE2
Details
Lead Sponsor:
University Health Network, Toronto
Treatments:
Psilocybin